Skip to content
XPR
content.
Press releases
Video
Podcasts
Op-eds
Lists
Guest posts
Author:
Revelation Biosciences, Inc.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
August 6, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
August 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
July 10, 2026